Ready to consummate its Shire buyout, Takeda plans US dual listing while NYSE loses a major pharma to Nasdaq
Taking another step in Takeda’s ascent into the top rank of global industry players, execs at the Japanese drugmaker say that by the time they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
